The overview presentation will review some of the Company’s recent achievements as well as the outlook for upcoming data milestones
JERUSALEM, Dec. 11, 2024 (GLOBE NEWSWIRE) — Alpha Tau Medical Ltd. (“Alpha Tau”, or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that CEO Uzi Sofer and CFO Raphi Levy will present a corporate overview and update at the J.P. Morgan 43rd Annual Healthcare Conference on Thursday, January 16, 2025 at 9:45am PT / 12:45pm ET, in San Francisco, CA, and will host institutional investor meetings at the event.
| Event: | J.P. Morgan 43rd Annual Healthcare Conference |
| Format: | Presentation and 1-on-1 Meetings |
| Date: | January 16, 2025 |
| Time: | 9:45AM PT – 10:25AM PT |
| Location: | Westin St. Francis, San Francisco, CA |
Webcast: Link located on the “Events & Presentations” page in the Investor Relations section on the Company’s website at https://www.alphatau.com/events
Please reach out to your J.P. Morgan representative to schedule 1-on-1 meetings with Mr. Sofer and Mr. Levy.
About Alpha Tau Medical Ltd.
Founded in 2016, Alpha Tau is an Israeli oncology therapeutics company that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. The technology was initially developed by Prof. Itzhak Kelson and Prof. Yona Keisari from Tel Aviv University.
About Alpha DaRT®
Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is designed to enable highly potent and conformal alpha-irradiation of solid tumors by intratumoral delivery of radium-224 impregnated sources. When the radium decays, its short-lived daughters are released from the sources and disperse while emitting high-energy alpha particles with the goal of destroying the tumor. Since the alpha-emitting atoms diffuse only a short distance, Alpha DaRT aims to mainly affect the tumor, and to spare the healthy tissue around it.
Investor Relations Contact:
IR@alphatau.com
Ad hoc announcement pursuant to Art. 53 LR 2025 marks a key execution year in…
Preliminary, directional read of planned 88-investor sample indicates heightened proof thresholds (unit economics, reimbursement, outcomes)…
• Patient 1 of Cohort 1 has now completed the 24-month follow-up timepoint, and at…
LegitScript-certified telehealth platform publishes consumer analysis as searches for GLP-1 weight loss information reach record…
Independent investigation examines castor oil, tea tree oil, and salicylic acid formulation claims in the…
Independent examination investigates SleepZee's moldable customization approach, medical-grade material claims, and manufacturer disclosure practices for…